Thomas Hach

1.7k total citations
38 papers, 1.2k citations indexed

About

Thomas Hach is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Thomas Hach has authored 38 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 16 papers in Endocrinology, Diabetes and Metabolism and 8 papers in Surgery. Recurrent topics in Thomas Hach's work include Diabetes Treatment and Management (15 papers), Metabolism, Diabetes, and Cancer (13 papers) and Multiple Sclerosis Research Studies (6 papers). Thomas Hach is often cited by papers focused on Diabetes Treatment and Management (15 papers), Metabolism, Diabetes, and Cancer (13 papers) and Multiple Sclerosis Research Studies (6 papers). Thomas Hach collaborates with scholars based in Germany, United States and Switzerland. Thomas Hach's co-authors include Ele Ferrannini, Stefan Hantel, Sabine Pinnetti, Susanne Crowe, Kevin D. Hall, Giulia Ferrannini, Arjun Sanghvi, Uli C. Broedl, Hans J. Woerle and H.J. Woerle and has published in prestigious journals such as New England Journal of Medicine, Circulation and Neurology.

In The Last Decade

Thomas Hach

36 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Hach Germany	15	827	506	436	182	135	38	1.2k
Wenjia Yang China	18	642 0.8×	310 0.6×	240 0.6×	120 0.7×	30 0.2×	59	1.1k
Hasan Altunbaş Türkiye	20	525 0.6×	201 0.4×	349 0.8×	69 0.4×	33 0.2×	49	1.1k
Phil Ambery United Kingdom	18	897 1.1×	449 0.9×	399 0.9×	313 1.7×	21 0.2×	57	1.3k
E. Blind Germany	15	479 0.6×	433 0.9×	239 0.5×	91 0.5×	69 0.5×	48	1.1k
Gonzalo Díaz-Soto Spain	16	413 0.5×	136 0.3×	341 0.8×	51 0.3×	64 0.5×	62	781
Antônio Ribeiro‐Oliveira Brazil	16	514 0.6×	167 0.3×	232 0.5×	54 0.3×	46 0.3×	59	898
Latika Sibal United Kingdom	13	459 0.6×	172 0.3×	230 0.5×	38 0.2×	54 0.4×	17	1.0k
Benjamin Bouillet France	24	966 1.2×	310 0.6×	567 1.3×	87 0.5×	104 0.8×	95	1.8k
Liru Qiu China	11	229 0.3×	236 0.5×	209 0.5×	47 0.3×	44 0.3×	32	712
Nobuhiro Ayuzawa Japan	18	464 0.6×	409 0.8×	213 0.5×	60 0.3×	39 0.3×	27	982

Countries citing papers authored by Thomas Hach

Since Specialization

Citations

This map shows the geographic impact of Thomas Hach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Hach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Hach more than expected).

Fields of papers citing papers by Thomas Hach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Hach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Hach. The network helps show where Thomas Hach may publish in the future.

Co-authorship network of co-authors of Thomas Hach

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Hach. A scholar is included among the top collaborators of Thomas Hach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Hach. Thomas Hach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Perkovic, Vlado, Jonathan Barratt, Brad H. Rovin, et al.. (2024). Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy. New England Journal of Medicine. 392(6). 531–543. 42 indexed citations

Rizk, Dana V., Dmitrij Kollins, Olympia Papachristofi, et al.. (2024). Safety and Efficacy of Iptacopan in Patients with IgA Nephropathy with Baseline eGFR 20 to <30 mL/min: Phase 3 APPLAUSE-IgAN Subcohort Results. Journal of the American Society of Nephrology. 35(10S). 1 indexed citations

Poeta, Maurizio Del, Brian J. Ward, Benjamin Greenberg, et al.. (2022). Cryptococcal Meningitis Reported With Fingolimod Treatment. Neurology Neuroimmunology & Neuroinflammation. 9(3). 17 indexed citations

Chitnis, Tanuja, Birgit Bauer, Giampaolo Brichetto, et al.. (2022). Patient-reported outcome measures in MS: Do development processes and patient involvement support valid quantification of clinically important variables?. Multiple Sclerosis Journal - Experimental Translational and Clinical. 8(2). 3090468842–3090468842. 6 indexed citations

Hach, Thomas, Kasra Shakeri‐Nejad, Marc Bigaud, et al.. (2022). Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence. Journal of Interferon & Cytokine Research. 43(6). 246–256. 6 indexed citations

Gold, Ralf, Ludwig Kappos, Amit Bar‐Or, et al.. (2022). Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. Journal of Neurology. 269(9). 5093–5104. 12 indexed citations

Arnold, Douglas L., Amit Bar‐Or, Ralph H. B. Benedict, et al.. (2022). Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial. Multiple Sclerosis Journal. 28(10). 1526–1540. 22 indexed citations

Ziemssen, Tjalf, Virender Bhan, Jeremy Chataway, et al.. (2022). Secondary Progressive Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation. 10(1). 33 indexed citations

Hemmer, Bernhard, Bruce Cree, Benjamin Greenberg, et al.. (2021). COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients. Neurology Neuroimmunology & Neuroinflammation. 9(1). 25 indexed citations

10.

Ziemssen, Tjalf, Gavin Giovannoni, Enrique Álvarez, et al.. (2021). Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey. Journal of Medical Internet Research. 23(10). e29558–e29558. 9 indexed citations

11.

Li, Yang, Minghui Ma, Xinmiao Huang, et al.. (2020). Improvement of long-term risks of cardiovascular events associated with community-based disease management in Chinese patients of the Xinjiang autonomous region of China. BMC Public Health. 20(1). 1034–1034. 2 indexed citations

12.

Ziemssen, Tjalf, Bryan Bennett, Chloe Johnson, et al.. (2020). A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study. Journal of Medical Internet Research. 22(2). e16932–e16932. 36 indexed citations

13.

Yoon, Kun‐Ho, Rimei Nishimura, Jisoo Lee, et al.. (2016). Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials. Diabetes Obesity and Metabolism. 18(10). 1045–1049. 18 indexed citations

14.

Chirila, Costel, et al.. (2015). Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Quality of Life Research. 25(5). 1199–1207. 6 indexed citations

15.

Nishimura, Rimei, Yuko Tanaka, Kazuki Koiwai, et al.. (2015). Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardiovascular Diabetology. 14(1). 11–11. 96 indexed citations

16.

Cherney, David Z.I., Mark E. Cooper, Ilkka Tikkanen, et al.. (2014). Abstract 16709: Contrasting Influences of Renal Function on Blood Pressure and HbA1c Reductions With Empagliflozin in Patients With Type 2 Diabetes and Hypertension. Circulation. 130(suppl_2). 1 indexed citations

17.

Ferrannini, Ele, Stefan Hantel, Sabine Pinnetti, et al.. (2013). Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin. Diabetes Care. 36(12). 4015–4021. 186 indexed citations

18.

Rosenstock, Julio, Leo Seman, Ante Jelaska, et al.. (2013). Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 ( SGLT2 ) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obesity and Metabolism. 15(12). 1154–1160. 183 indexed citations

19.

Först, Thomas, Thomas Hach, T. Kunt, Matthias M. Weber, & Andreas Pfützner. (2009). Molecular Effects of C-Peptide in Microvascular Blood Flow Regulation. The Review of Diabetic Studies. 6(3). 159–167. 9 indexed citations

20.

Hach, Thomas, Thomas Först, T. Kunt, et al.. (2008). C‐Peptide and Its C‐Terminal Fragments Improve Erythrocyte Deformability in Type 1 Diabetes Patients. Journal of Diabetes Research. 2008(1). 730594–730594. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact